Search Results

Nuvectis Pharma, Inc. today provided highlights from the poster presentation of NXP800 that took place yesterday at the American Association for Cancer Research (“AACR”) Annual Meeting 2023 in Orlando, FL (to view the poster, titled Inhibition of HSF1 Demonstrates Therapeutic Efficacy in Preclinical PDX Models of Human Cholangiocarcinoma.

The rise in support for cancer research is escalating the growth of patient derived xenograft (PDX) models market. Global Patient Derived Xenograft (PDX) Models Market was valued at USD 142,396.93 million in 2021 and is expected to reach USD 500,362.17 million by 2029, registering a CAGR of 17.01% during the forecast period of 2022-2029.

Crown Bioscience announced their newly published study in PLOS ONE, a journal of the Public Library of Science, demonstrating the establishment and application of a highly clinically relevant 3D in vitro PDX-derived organoid biobank for higher-throughput screening for cancer drug discovery.

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the ability to conduct preclinical cancer research using ITCC-P4’s well-characterized collection of 400 annotated pediatric cancer models.

Today, Change Healthcare (Nasdaq: CHNG) announced the acquisition of PDX, a leader in providing patient centric and innovative technologies for pharmacies and health systems.

Agreement adds 350 premium tumor PDX models to world’s largest PDX collection